August 7, 2023 Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis View Article
September 21, 2022 Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS) View Article
June 3, 2022 Glatiramer Acetate Depot Shows Safety, Effectiveness in Progressive MS, Interim Results Suggest View Article
March 30, 2022 Mapi Pharma Receives U.S. Patent Covering Methods of Suppressing or Alleviating Primary or Secondary Progressive Multiple Sclerosis with a Sustained Release Glatiramer Acetate Depot View Article
December 21, 2020 Mapi Pharma Provides Enrollment Update in Phase III GA Depot Clinical Trial View Article
September 10, 2020 Mapi Pharma Presents Glatiramer Acetate Depot (GA Depot) Results at the 8th Joint ACTRIMS-ECTRIMS Meeting MSVirtual2020 View Article
October 28, 2019 Mapi Announces First Patient Enrolled in the Phase III Clinical Trial of GA Depot for Relapsing Multiple Sclerosis (RMS) View Article
